

Primary Central Nervous System Lymphoma (PCNSL) Survey from The End Brain Cancer Initiative and Ono Pharma

Primary Central Nervous System Lymphoma (PCNSL) Survey from The End Brain Cancer Initiative and Ono Pharma to collect the thoughts of patients/care partners.

REDMOND, WA, UNITED STATES,
December 4, 2024 /EINPresswire.com/
-- Contact: Dellann Elliott Mydland, 425-785-8489,
Dellann@EndBrainCancer.org

The End Brain Cancer Initiative (EBCI) has partnered with Ono Pharma to collect the thoughts of patients and care partners in order to improve and increase available resources for the Primary Central Nervous System Lymphoma (PCNSL) community, and how they want to receive this info. Patients who have been diagnosed with PCNSL or their care partners can share their experiences and insights through a short survey.

Patients or care partners interested in sharing their insights to improve resources for the PCNSL community should visit endbraincancer.org/pcnsl and fill out the Interest Form by January 31, 2025. This page also includes information about PCNSL and firsthand stories from members of the PCNSL community.

About ONO PHARMA USA

ONO PHARMA USA, established in 1998 as the U.S. subsidiary of [Ono Pharmaceutical](http://Ono Pharmaceutical Co., Ltd.) Co., Ltd., is pursuing the clinical development of new drug candidates and aiming to establish operations in the U.S., from clinical development to regulatory approval and commercialization. In addition, ONO PHARMA USA is engaged in promotion of the discovery alliances and licensing activities to expand Ono's development pipeline and pursue the commercialization opportunities in the U.S. For more information, please visit us.ono-pharma.com.



About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.,
headquartered in Osaka, is an R&D-
oriented pharmaceutical company
committed to creating innovative
medicines in specific areas. Ono
focuses its research on oncology,
immunology, neurology, and specialty
area with high medical needs as
priority areas for discovery and
development of innovative medicines.
For further information, please visit the
company's website at
<https://www.ono-pharma.com/en>.

About the End Brain Cancer Initiative
To support/donate to the End Brain
Cancer Initiative's increased access and
health delivery for patients, mission,
services and programs, please visit
EndBrainCancer.org

The End Brain Cancer Initiative (EBCI) is
a 501(c)3 non-profit patient advocacy
organization focused on disease
education, awareness, outreach,
increasing patient access and
improving Standard of Care. The End
Brain Cancer Initiative, formerly known as the Chris Elliott Fund (CEF), is dedicated to ensuring
that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain
have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation.
We believe that IMMEDIATE ACCESS to these options provides this patient community with the
best HOPE for survival and sustained quality of life. We partner with industry, patients,
researchers, advocacy groups, medical teams, hospital networks and others to educate patients
and their caregivers so they can have empowered conversations with their medical teams. Learn
more about the End Brain Cancer Initiative at EndBrainCancer.org.

Dellann Elliott Mydland, End Brain Cancer Initiative, 425-785-8489, Dellann@EndBrainCancer.org

Dellann Elliott Mydland
End brain cancer Initiative
+ +1 425-444-2215
[email us here](#)



Dellann Mydland Elliott President & Chair, EBCI



ONO PHARMA

ONO

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/765912779>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.